PET Imaging with 62Cu-ETS in a human clinical trial at the university of wisconsin - madison
PET Imaging with 62Cu-ETS in a human clinical trial at the university of wisconsin - madison
复制标题
威斯康星大学麦迪逊分校的人体临床试验中使用 62Cu-ETS 进行 PET 成像
DOI：
10.1109/nssmic.2007.4436996
复制
发表时间：
2007
期刊：
影响因子：
--
通讯作者：
C. Stone
中科院分区：
文献类型：
--
作者：
J. Lacy;L. Guerrero;R. Chiu;Liang Sun;L. Hall;C. Stone
铜（II）双（缩氨基硫脲）化合物显示出在正电子发射断层扫描（PET）测量组织血流量的临床应用前景。62 Cu-PTSM已被广泛评价为心肌和通用流动剂。虽然是一种有效的药物，但其在人血浆中表现出白蛋白结合，这限制了其在高血流成像中的性能。一种新的试剂，62 Cu-ETS，没有表现出这种白蛋白结合的物种分化。在本研究中，对10名健康人类志愿者进行62 Cu-ETS PET成像，以通过测量一般解剖结构周围的限定感兴趣区域（ROI）内的计数密度并除以注射剂量，校正注射部位的损失，获得主要器官（包括血液、脑、肾、肝、肺和心肌）的注射剂量百分比值。然后将这些结果与先前使用相同成像方法完成的类似62 Cu-PTSM PET成像研究进行比较。为了进行有效比较，使用与62 Cu-ETS研究相同的ROI程序重新分析了62 Cu-PTSM研究的数据。62 Cu-ETS显示出与62 Cu-PTSM相似的心肌摄取，但肾脏摄取比静息心肌高2倍，而62 Cu-PTSM仅为1.3倍。因此，62 Cu-ETS显示出很高的应用前景，充血心肌流量测量以及肾脏成像的重要应用。62 Cu-ETS的另一个优点是，相对于62 Cu-PTSM，可干扰心肌成像的肝脏摄取减少约2倍。
Copper(II) bis(thiosemicarbazone) compounds show promise for clinical use in the measurement of tissue blood flow with positron emission tomography(PET). 62Cu-PTSM has been extensively evaluated as a myocardial and general purpose flow agent. Although an effective agent, it exhibits albumin binding in human plasma which limits its performance in high blood flow imaging. A new agent, 62Cu-ETS, exhibits no such species differentiation of albumin binding. In this study, ten healthy human volunteers were subjected to 62Cu-ETS PET imaging to obtain percent injected dose values for major organs, including the blood, brain, kidneys, liver, lungs, and myocardium, by measuring count densities within defined regions of interest (ROI's) around the general anatomical structure and dividing by the injected dose, correcting for losses at the injection site. These results were then compared to an analogous 62Cu-PTSM PET imaging study completed previously utilizing the same imaging methods. For effective comparison, data for the 62Cu-PTSM study was reanalyzed using the same ROI procedure as was performed on the 62Cu-ETS study. 62Cu-ETS shows similar myocardial uptake compared to 62Cu-PTSM, but kidney uptake is two fold higher than resting myocardium compared with only 1.3 fold for 62Cu-PTSM. Hence 62Cu-ETS shows high promise for the important application of hyperemic myocardial flow measurement as well as renal imaging. An additional advantage of 62Cu-ETS is that liver uptake which can interfere with myocardial imaging is reduced by about 2 fold relative to that of 62Cu-PTSM.
PET 灌注剂 Copper-62-PTSM 的人体生物分布和剂量测定。
DOI：
--
发表时间：
1998
期刊：
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
影响因子：
--
作者：
Wallhaus,TR;Lacy,J;Whang,J;Green,MA;Nickles,RJ;Stone,CK
通讯作者：
Stone,CK